<SEC-DOCUMENT>0001213900-26-043235.txt : 20260414
<SEC-HEADER>0001213900-26-043235.hdr.sgml : 20260414
<ACCEPTANCE-DATETIME>20260414082328
ACCESSION NUMBER:		0001213900-26-043235
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260414
FILED AS OF DATE:		20260414
DATE AS OF CHANGE:		20260414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clearmind Medicine Inc.
		CENTRAL INDEX KEY:			0001892500
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41557
		FILM NUMBER:		26859245

	BUSINESS ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
		BUSINESS PHONE:		972-54-5704749

	MAIL ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0286258-6k_clearmind.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
of Foreign Private Issuer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 13a-16 or 15d-16</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of: April 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-41557</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>CLEARMIND
MEDICINE INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>101
&ndash; 1220 West 6th Avenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vancouver,
British Columbia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attached
hereto and incorporated herein is the Registrant&rsquo;s press release issued on April 14, 2026, titled &ldquo;Clearmind Medicine&rsquo;s
CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
INDEX</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea028625802ex99-1.htm">Press release titled: &ldquo;Clearmind Medicine&rsquo;s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clearmind
    Medicine, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 14, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <I>Adi
    Zuloff-Shani</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adi
    Zuloff-Shani</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea028625802ex99-1.htm
<DESCRIPTION>PRESS RELEASE TITLED: "CLEARMIND MEDICINE'S CMND-100 MEETS PRIMARY ENDPOINT IN FDA-APPROVED PHASE I/IIA CLINICAL TRIAL FOR ALCOHOL USE DISORDER"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="ea028625802_ex99-1img1.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Clearmind Medicine&rsquo;s
CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vancouver,
Canada, April </FONT>14<FONT STYLE="font-family: Times New Roman, Times, Serif">, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq:
CMND) (&ldquo;Clearmind&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage biotech company focused on the discovery and development
of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, </FONT>today
announced that CMND-100, the Company&rsquo;s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol
Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Results from the third
cohort of the trial indicated a high safety profile for CMND-100, even at the higher dosage administered to date. The data demonstrated
that the drug candidate was well tolerated, with no serious adverse events reported in the third cohort and continued favorable overall
tolerability, consistent with the safety outcomes observed in prior cohorts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Phase I/IIa clinical
trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy
of CMND-100 in patients with moderate to severe AUD. Meeting the primary safety and tolerability endpoint in this dose-escalation stage,
including at the higher dosage in the third cohort, supports continued advancement of CMND-100 as a potential novel, non-hallucinogenic
treatment option for AUD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>About&nbsp;Clearmind&nbsp;Medicine
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Clearmind is a clinical-stage
neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived
therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research
and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company&rsquo;s intellectual
portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents
for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build
its portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Shares of Clearmind are
listed for trading on Nasdaq under the symbol &ldquo;CMND.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
further information, visit:&nbsp;https://www.clearmindmedicine.com</FONT>&nbsp;or contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">invest@clearmindmedicine.com</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif">www.Clearmindmedicine.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Forward-Looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release contains
&ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation Reform Act and other securities laws.
Words such as &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo;
&ldquo;estimates&rdquo; and similar expressions or variations of such words are intended to identify forward-looking statements. For example,
the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials. Forward-looking statements
are not historical facts, and are based upon management&rsquo;s current expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith.&nbsp;However, there can be no
assurance that management&rsquo;s expectations, beliefs and projections will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties
that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more
detailed description of the risks and uncertainties affecting the Company, reference is&nbsp;made to the Company&rsquo;s reports filed
from time to time with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), including, but not limited to, the risks detailed in
the Company&rsquo;s annual report on Form 20-F for the fiscal year ended October 31,&nbsp;2025&nbsp;and subsequent filings with the SEC.
Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking
statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting
forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking
statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking
statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not
incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028625802_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028625802_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  I 0T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^QW]MG]MO
MX"?L'_ OQ'\=/CWXB_LS0+ R:+X;\.:7)'-XM^(GC.2UN'T[P=X0TQ)EDN-4
MEN(1'=7 C:TT"W$VJ:S-9Z?9W-PG\"W[9_\ P7D_X* ?M5:]JUEX*^*&O?LH
M?"B.[U*WTGX8_ _6[KPEXM;2=SC3[KQ?\3=,>#QG=:E=:>5GU/3O"VK^%M $
MI83Z5?*SS/'_ ,%YOVR=;_:N_P""@/Q-\'6NJR2?";]E+7M:^!OPVT6VNI3I
MMSXH\+W/V;XH^+)K59&L[C4-3\?6>J^%-)U.5&F@\->&].FC++?.9?FO_@FO
M_P $UOC5_P %(_C)J'PR^%]W9^#? _@:"WUCXL?%O7;.\GT?P9IEW/(NBVMG
M:V\UO<^)?&OB1XK@Z=H[S6XM8[::[U/[+:VSJ_T>7X'!8>B\?CJ<I.:=GROE
M2[MM6T[_ / .>M6J2E%0C)MRBKI-I-M:NVEEN]=$?$ES\1_BGJ6KG7[_ .)_
MQ2U?7A%'<OXBU;XF^.M2\3*2YD:__M>]UN;4MDTC;@RWD1N"0$E+8K]%_P!E
M/_@LI_P42_9%UK3'\/\ [0OC?XN_#S394CUGX3?M">)-:^*WAJ\TJ4QS3V>F
M:[XON;GQYX)OFA4KHXT7Q&;"R>0R-IE];AK9OZK="_X-9_V!;'P<-#\0>.OV
MD_$7B_RI#-X]@\=>&]%C;4I(L2ZC;>#8_"EYI"V\\F ^GWEW>@1@;)H7!<_G
M1+_P:F_%EOVCH_#Y_:.T67]DN.T&JKX^_LJ:+XX+$TD,=QX$3P>T]QX6DU60
M233V_C%M1CT>VM[?(\.M=R11+U3SC)\33="="2A2B^5R5N:RLN6^_?1WW]!N
M&)M[TKQTNDGKJO\ @/3_ #/Z._\ @F%_P5 ^!?\ P4E^&VM^(?!0D^'_ ,9/
M!?\ 9D/QB^ OB+5+6[\4> KNX1H+/7-(GA%M%XH^'WB!XMVA^+K.T7S;O[3I
MVJF"ZBM(!^H<3(ZDHRN V,JP8=%/4$]00>O0@]"*^+OV//V#/V9?V%/AXWP\
M_9M^%6E>"8;AK9_$?BZ[,>M?$/XB75F5FM[_ ,?^.KH?VSKK+=&>>WTYOLVC
M:*]Q=1:)I>GPW-PLOV/I\,D$'E/E51@D4;8)C1(HXV&X$[Q),DLZ,?FV3*K
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M95G?6A42&=':X2*2(JXNFEB=V2$P31*[75LY96M'+2,RS!@Q$JL_XP?MW_\
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M]J$&I^(M-73I9H9_%_PS\4W!GU.72+.7^TM'OWB&GV(LYIS'_3?XQ_X.*O\
M@E3HO@N\\0:7\=O$GC#4SITLL7@SP?\ ##QM?>,_/FA?[-;/8:EH4&EVDTLA
M6)9;ZZ>RC9M]R#"KBE7P&,EB9SCAYRI5J]6<9IP:E!R5FK3ND[K=)VNW9)V<
M:M-1LY?A+_Y$_96+6[2*Y2S-Y,MS<)=W5O:2/)'>7BVLD<%Q=6EM!)'J&KVR
M^?#<3WMM9W4=K;>5++L6:WE?\(O^#E.42_\ !*[QF0T8 ^-WP&!A0@O!*?%W
MF213CS)'69"VV02,'##;CC+?Q_?MZ_MX?'C_ (*B?MI?#_QC\,O"_BGP?JNF
MZSH_P?\ V2_A+X!UV_3QIX>?4?$-G<1S-XC\*7&GO#XIU[7HM,\0>,+BQN6T
M[PIHFAVDWVBVTOPT[+_35_P61^$?Q!^!/_!!'P'\*_B[\4/&7QD^+7@WQ7^S
M9IWQ-^)/Q \8:UXZ\4^)/'%SXLFU3Q.;_P 3^(-2UC6]5LM+UN_OM(T2XU/4
M;R?^R;"U D5BP'7# T\+CLME4M"<:L:LHW4G"$GR\SE%R5G*+5D[IK6-M\ZL
MXRBU%WTDMI;V>GPK]?\ +RS_ (-0)EM?@G^V?>2R^1;V7Q7^'M[>38#".RMO
M!-Y+=N,9D69+=9)(9(QN3RY%ZOQ_,MXB^/7@O_@H'_P4%N_C]^V=\4O$'P\^
M!OQ8^)&K:_XMUS2[3Q+XCNO 'P&\-)JMU\-?AGX TG3HM2.BWL?A;3-"TIM3
MATV?R/$VNZ_XF6.2YO5K^F7_ (-1K=+SX'_MH6$D1N+?4?BO\.M/NC!<)#+#
M;ZEX+O--GD1I4924MKV>8?*WSPH@4O*F/Y=/A[\+/A#^R!^W;'\ _P!O_P"'
M/B#Q;\)O@M\0]>^&WQF\,:1J/B+P]XC;P_#:MH_@GXD>'[OPY<V.M:CHTFFP
MZ%XUTVSL)'FUW0;IX+8&_5HQZ=!1J9IFTV_WD*<)TK;R3I7@TV[7:U2=DM/-
M+GAI%)WWD]I=_)?U]Y^[/[0VG_\ !LWXS^ WB;P/\%?%VH?!_P"*VG>%-1?X
M<?%S1M&_:-O/$UYXKTNSO1I%]XPL_$YN?#WB?3/%-_%<1>)AK&D6JS3ZA>WM
MDUKYC*?!O^#8C]HSQ-\,?VW-9_9\DU80?#K]I#X:ZYJ&H^'#<&+PY;_$_P"'
MFDV.KZ+XDT?2@8+2SO#X8AU+PW=*D2/+X771M-OP;W2Y96_23QW^RQ_P:]>"
M?A%J'QE7QUX"\2:)!X>GU?2/#7@[]JCXK:K\1_$-[';&[L-&L/ ^F>-$\16N
MO:CNM].OH]5TB)M-NI?L^I2VWV:1ZX+_ ((1ZW_P3?\ CS^U99Z_\%/V#_C)
M\#_VAOAKX&\0^+I?B-=_&SQM\3?A]I/ACQ!._AJ[36G\0ZY!=:3KOB.#48HX
M;2XTJ6/^T;C4K33[R6UT.22N:$Y5<#B'6P]1J+:G4J2B[2U]Z\Y)N]DY64E?
M^571=U?_ "3_ "M]W],9_P %.?\ @CGKGQ*_;A\5?MI?M._MR_L]> _@7\6/
MBAX6M_$=I\1-<'PW\8>#/@;X/MM(\.Z?\-?AM=ZFVH>'O%VO:)H5G-]JDL+0
M-)XJUB\UD@ZWYD[?.7_!1O0/^#>#0/V4_&_A+]D#6?#"_M*Z!H.CS_"CQ+\%
MYOC%XCU#Q)X@L4L;&WM/B?XUU\1^"/%>@WUM=W4^HK/JCW.EW.RYM[$2QB%_
MRX_;0\=^)/VV/^"L/C^R_:M^)=QX%\*3_M7:O\!(-8\2M:WND?L^?!CPMXXU
M+X;0:7X;T/4C>^'O#MK;6WAH_P#"0:I'96UWK?C2^'B?6KN74;BYN&_</_@I
M9^P'_P $7/V ?V*_B1K/@33=(^(O[37C3P\_AGX$7/BGX]^(?B-XVU'Q3JL^
MDQS^.]/\,^']>?P_9V.C:3(VJZEJDWARWTR#3XX40^?.BKBHSIK*VZU11A-R
M<53J6A";3A>2@TTXRAU=H:+N)M-/3H]T[O1]+:7_ #.7_P"#33Q[XHLOBW^V
ME\(8;Z1/ VH>!_@]\79]&5@MI'XZB\0>)O!6MZ[8VYS;V=_K/A]]'L/$-ZD?
MVK7;'P]X?M7>)],\QOQM_P""UD,\O_!5O]ML6T,MQ</\4O#\-M! S"66ZG\
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MBVT]I4>JTBJT$Y;]'IW\BKI2K/7WG&VCUM&SMIW31_/=_P $&?\ @DK\#O\
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M]9'_  6)_P""U/['S?L5_%;X!?LR_&'PE\>/C+\?O!VH?#6VM/AW-<Z]X8\
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M_P R#2;JT:.VO=\#6\4)E.IE[=FMK4XV21W5FL<2-"3\KWLTA.3YCC!->V>
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MPA#;V^K7OBS3;J\BOX/"L5],\]E;_9Y+R6! \4*2R?J9_P %)_V#](_X*/\
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.;1+T]!^SCV7W?Y(__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
